Anticancer research
-
Anticancer research · Sep 2015
Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy.
The prognosis of patients with locally advanced esophageal squamous cell carcinoma (LAESC) is extremely poor. The impact of adverse effects of chemoradiotherapy (CRT), particularly myelosuppression, on postoperative long-term results has remained unclear. ⋯ Pre-operative CRT-induced myelosuppression has a negative impact on the prognosis of patients with LAESC. Our findings indicate that a careful postoperative follow-up is required for patients who develop myelosuppression after neoadjuvant CRT followed by curative resection for locally advanced esophageal cancer.
-
Anticancer research · Sep 2015
Comparative StudyComparison of GFP-Expressing Imageable Mouse Models of Human Esophageal Squamous Cell Carcinoma Established in Various Anatomical Sites.
Esophageal squamous cell carcinoma (ESCC) is a recalcitrant cancer. Mouse models of this disease could be used for discovery of more effective therapy for ESCC. ⋯ The mouse xenograft models of ESCC developed in the present study can provide a means of discovering more effective therapy of this recalcitrant type of cancer.
-
Anticancer research · Sep 2015
Case ReportsPalliative Pelvic Exenteration for Pelvic Recurrence Invading the Sciatic Foramen with Chronic Cutaneous Perineal Fistula after Radical Surgery for Cervical Cancer: A Case Report.
Pelvic exenteration remains one of the most aggressive gynecological surgical procedures performed for patients with locally-invasive cervical cancer, usually performed with curative intent. However, there exist patients who present in a very advanced stage of the disease, in which only a palliative surgical procedure can be performed. Although in these cases the survival benefit is minimal, performing a pelvic exenteration significantly improves the quality of life. We present the case of a 63-year-old female who was submitted to palliative pelvic exenteration for a locally invasive recurrence in the left sciatic foramen after surgically-treated cervical cancer.